Drugs / GLPG0187
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01313598 | Mar 2011 → May 2013 | cancer | Lakefront Biotherapeutics NV | Completed | No outcome recorded |
| Phase 1 | NCT00928343 | Jun → Nov 2009 | — | Lakefront Biotherapeutics NV | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2010-01-19 | Lakefront Biotherapeutics NV | Results Galapagos candidate metastasis drug shows good safety and biomarker response lakefrontbio.com ↗
Galapagos NV (Euronext: GLPG) announced results from the first-in-human trial with candidate drug GLPG0187. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2010-04-19 | Lakefront Biotherapeutics NV | Galapagos to present GLPG0187 first-in-human trial results (cancelled) lakefrontbio.com ↗ |
| 2010-01-19 | Lakefront Biotherapeutics NV | Galapagos candidate metastasis drug shows good safety and biomarker response lakefrontbio.com ↗ |
| 2009-06-16 | Lakefront Biotherapeutics NV | Galapagos initiates clinical studies with GLPG0187, a candidate drug for bone metastasis lakefrontbio.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GLPG0187 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01313598 ↗ |
| Modality | Small molecule | — CHEMBL3319236 ↗ |
| Route | Subcutaneous | “Single ascending subcutaneous doses (subcutaneous solution)” NCT00928343 ↗ |